STOCKS | Galderma Shares Slide After FDA Rejects Botox Rival Relfydess
2026-07-01 08:06:37
Galderma Group AG shares fell the most in more than a year after the Swiss dermatology company said the US Food and Drug Administration turned down its Botox rival treatment, Relfydess, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
ING’s Turner Expects Dollar to Stay Firm if Fed Chair Warsh Stresses Price StabilityNext article：
Solana链上每日代币发行量创80天新高
